Cartilage matrix protein (226-234)

Cartilage matrix protein (226-234) is a synthetic peptide fragment derived from the central extracellular matrix component known as cartilage matrix protein, also referred to as matrilin-1. This non-collagenous glycoprotein is integral to cartilage structure and function, participating in the formation and stabilization of the cartilage extracellular matrix through interactions with collagen fibrils and other matrix molecules. The 226-234 peptide segment represents a defined sequence within the parent protein, making it a valuable molecular tool for researchers studying protein-protein interactions, cartilage biology, and extracellular matrix dynamics. Its distinct amino acid sequence allows for targeted investigation of structure-function relationships and signaling pathways relevant to cartilage development, maintenance, and pathology.

Peptide interaction studies: As a defined fragment of matrilin-1, the 226-234 peptide is widely used in studies probing specific protein-protein interactions within the cartilage extracellular matrix. By incorporating this peptide into binding assays, researchers can dissect the binding affinities and interaction domains between cartilage matrix protein and other matrix constituents, such as collagens, proteoglycans, or integrins. These experiments provide mechanistic insights into how this region of the protein contributes to matrix assembly, stability, and cellular signaling in chondrocytes.

Epitope mapping: The 226-234 sequence is often utilized as a reference epitope in immunological assays designed to characterize antibody specificity and binding sites. By synthesizing and employing this peptide in ELISA, Western blot, or immunoprecipitation protocols, investigators can map the antigenic regions of matrilin-1 recognized by monoclonal or polyclonal antibodies. This approach is essential for developing and validating immunoreagents for cartilage research and for understanding autoimmune responses targeting cartilage matrix proteins.

Cartilage degeneration research: The peptide serves as a molecular probe in studies of cartilage degradation, particularly in models of osteoarthritis and other degenerative joint diseases. Researchers use the 226-234 fragment to monitor proteolytic cleavage events, assess the release of matrix components, and evaluate the activity of matrix metalloproteinases or aggrecanases. Such investigations help elucidate the molecular mechanisms underlying cartilage breakdown and facilitate the identification of potential biomarkers for disease progression.

Peptide-based assay development: The defined sequence of the 226-234 peptide lends itself to the development of synthetic peptide assays for quantifying matrix protein fragments in biological samples. These assays are instrumental in biomarker discovery, enabling the detection and quantification of cartilage matrix turnover products in tissue extracts, synovial fluid, or culture media. The use of standardized peptide fragments improves assay specificity and reproducibility, supporting both basic and translational research applications.

Structural and functional analysis: The 226-234 peptide is frequently employed in biophysical and structural studies aimed at elucidating the conformational properties of matrilin-1 domains. By analyzing this peptide using techniques such as NMR spectroscopy, circular dichroism, or molecular modeling, scientists can gain detailed information about secondary structure, folding propensity, and the influence of post-translational modifications. These data contribute to a deeper understanding of how specific sequence motifs govern the overall architecture and function of the cartilage extracellular matrix.

1. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review

2. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

3. Investigating Potential Interactions Between Neurohypophyseal Peptides, their Drug Analogs, and Coagulation Factor VIII

4. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics

5. High fat diet and GLP-1 drugs induce pancreatic injury in mice